Ropinirole for restless legs syndrome: A placebo-controlled crossover trial

C. H. Adler, R. A. Hauser, K. Sethi, J. N. Caviness, L. Marlor, W. M. Anderson, J. G. Hentz

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

Original languageEnglish (US)
Pages (from-to)1405-1407
Number of pages3
JournalNeurology
Volume62
Issue number8
DOIs
StatePublished - Apr 27 2004

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Adler, C. H., Hauser, R. A., Sethi, K., Caviness, J. N., Marlor, L., Anderson, W. M., & Hentz, J. G. (2004). Ropinirole for restless legs syndrome: A placebo-controlled crossover trial. Neurology, 62(8), 1405-1407. https://doi.org/10.1212/01.WNL.0000120672.94060.F1